Invention Grant
- Patent Title: Sulfonamide derivative or pharmaceutically acceptable acid-addition salt
-
Application No.: US16772314Application Date: 2018-12-11
-
Publication No.: US11673867B2Publication Date: 2023-06-13
- Inventor: Hiroshi Nagase , Tsuyoshi Saitoh , Masashi Yanagisawa , Yoko Irukayama
- Applicant: University of Tsukuba , BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
- Applicant Address: JP TX Tsukuba
- Assignee: University of Tsukuba,BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
- Current Assignee: University of Tsukuba,BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
- Current Assignee Address: JP Tsukuba; US TX Austin
- Agency: Leydig, Voit & Mayer, Ltd.
- Priority: JP 2017238093 2017.12.12
- International Application: PCT/JP2018/045523 2018.12.11
- International Announcement: WO2019/117148A 2019.06.20
- Date entered country: 2020-06-12
- Main IPC: C07D239/10
- IPC: C07D239/10 ; A61P3/04 ; A61P3/10 ; A61P25/24 ; A61P25/26 ; A61P25/00 ; A61K9/00
Abstract:
The present invention aims to provide a novel low-molecular-weight compound showing an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I):
wherein each symbol is as described in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.
wherein each symbol is as described in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.
Public/Granted literature
- US20210078955A1 SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID-ADDITION SALT Public/Granted day:2021-03-18
Information query
